QUESTCOR PHARMACEUTICALS INC

Operating margin

325.5%

Net margin

28.9%

Return on equity

9.8%

Return on assets

5.3%

Return on capital (ROCE)

76.5%

Liabilities / assets

45.8%

Debt / equity

0.84×

Book value / share

$6.82

Revenue growth (YoY)

40.8%

Net income growth (YoY)

1.4%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

9.01safe

Accruals / assets

−40.6%clean

Beneish M-Score

-1.22elevated

Piotroski F-Score

4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Amended charter or bylawsAug 20, 2014
• Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Shareholder vote · Other material eventAug 14, 2014
• Other material eventJul 30, 2014
• Results of operationsJul 25, 2014
• Other material eventJul 10, 2014
• Director / officer changeMay 16, 2014
• Results of operationsMay 6, 2014
• Entered a material agreement · Director / officer change · Regulation FD disclosureApr 7, 2014

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.